Bibliography
- Cavero I. Safety Pharmacology Society: 7th Annual Meeting 19-20 September, 2007, Edinburgh, UK. Expert Opinion Drug Saf 2008;7:91-100
- Available from: https://www.safetypharmacology.org/am12speakers.asp
- Cavero I, Crumb W. Safety Pharmacology Society: 5th Annual Meeting, 27 – 29 September, 2005, Mannheim, Germany. Expert Opinion Drug Saf 2006;5:181-5
- Cavero I. Safety Pharmacology Society: 6th Annual Meeting 26-28 September, 2006, San Diego, USA. Expert Opinion Drug Saf 2007;6:87-92
- Cavero I. Safety Pharmacology Society: 8th Annual Meeting 22-25 September, 2008, Madison, USA. Expert Opinion Drug Saf 2009;8:1-11
- Cavero I. Safety Pharmacology Society: 9th Annual Meeting 15-18 September, 2009, Strasbourg, France. Expert Opin Drug Saf 2010;9:365-78
- Cavero I. 10th Annual Meeting of the Safety Pharmacology Society: an overview. Expert Opin Drug Saf 2011;10:319-33
- Cavero I. 2011 Annual Meeting of the Safety Pharmacology Society: an overview. Expert Opin Drug Saf 2012;11:341-53
- Booth B, Zemmel R. Quest for the best. Nat Rev Drug Discov 2003;2:838-41
- Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42
- Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80
- Available from: www.pennmedicine.org/homecare/hcp/elig_worksheets/Karnofsky-Performance-Status.pdf
- Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57:1116-23
- Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47
- Rinaldi DA, Kuhn JG, Burris HA, et al. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 1999;44:372-80
- Hazarika M, White RM Jr, Booth BP, et al. Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res 2005;11:982-92
- Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44
- Available from: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f5a860f3-37ec-429c-ae04-9c88d7c55c08
- Thacker CA, Weiss GJ, Tibes R, et al. 18-FDG PET/CT assessment of basal cell carcinoma with vismodegib. Cancer Med 2012;1:230-6
- Chin L, Andersen JN, Futreal PA. Cancer genomics: from discovery science to personalized medicine. Nat Med 2011;17:297-303
- Smith KT, Workman JL. Histone deacetylase inhibitors: anticancer compounds. Int J Biochem Cell Biol 2009;41:21-5
- Bertino EM, Otterson GA. Romidepsin: a novel histone deacetylase inhibitor for cancer. Expert Opin Investig Drugs 2011;20:1151-8
- Sissung TM, Gardner ER, Piekarz RL, et al. Impact of ABCB1 allelic variants on QTc interval prolongation. Clin Cancer Res 2011;17(4):937-46
- ICH harmonised tripartite guideline: nonclinical evaluation for anticancer pharmaceuticals S9. 2009. Available from: www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S9/Step4/S9_Step4_Guideline.pdf
- Vargas HM, Bass AS, Breidenbach A, et al. Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. J Pharmacol Toxicol Methods 2008;58:72-6
- Pammolli F, Magazzini L, Riccaboni M. The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov 2011;10:428-38
- Stortecky S, Suter TM. Insights into cardiovascular side-effects of modern anticancer therapeutics. Curr Opin Oncol 2010;22:312-17
- ICH harmonised tripartite guideline: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. E14. 2005. Available from: www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html
- Naing A, Veasey-Rodrigues H, Hong DS, et al. Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. Ann Oncol 2012;23:2960-3
- Vargas HM, Amouzadeh HR, Engwall MJ. Nonclinical strategy considerations for safety pharmacology: evaluation of biopharmaceuticals. Expert Opin Drug Saf 2013;12:91-102
- ICH harmonised tripartite guideline: safety pharmacology studies for human pharmaceuticals. S7A. 2000. Available from: www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7A/Step4/S7A_Guideline.pdf
- ICH harmonised tripartite guideline: the non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. S7B. 2005. Available from: www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7B/Step4/S7B_Guideline.pdf
- Redfern WS, Valentin JP. Trends in safety pharmacology: posters presented at the annual meetings of the Safety Pharmacology Society 2001-2010. J Pharmacol Toxicol Methods 2011;64:102-10
- Redfern WS, Ewart LC, Lainée P, et al. Functional assessments in repeat-dose toxicity studies: the art of the possible. Toxicol Res 2013; In press
- Heyen JR, Blasi ER, Nikula K, et al. Structural, functional, and molecular characterization of the SHHF model of heart failure. Am J Physiol Heart Circ Physiol 2002;283:H1775-84
- Jurcut R, Wildiers H, Ganame J, et al. Detection and monitoring of cardiotoxicity-what does modern cardiology offer? Support Care Cancer 2008;16:437-45
- Jurcut R, Wildiers H, Ganame J, et al. Strain rate imaging detects early cardiac effects of pegylated liposomal doxorubicin as adjuvant therapy in elderly patients with breast cancer. J Am Soc Echocardiogr 2008;21:1283-9
- Stoodley PW, Richards DA, Meikle SR, et al. The potential role of echocardiographic strain imaging for evaluating cardiotoxicity due to cancer therapy. Heart Lung Circ 2011;20:3-9
- Available from: www.hesiglobal.org/i4a/pages/Index.cfm?pageID=3494
- Cavero I. Cardiovascular system assessment best practices: a Safety Pharmacology Society meeting. 11-12 May, 2010, Cambridge, MA, USA. Expert Opinion Drug Saf 2010;9:855-66
- Leishman DJ, Beck TW, Dybdal N, et al. Best practice in the conduct of key nonclinical cardiovascular assessments in drug development: current recommendations from the Safety Pharmacology Society. J Pharmacol Toxicol Methods 2012;65:93-101
- Bass A, Kinter L, Williams P. Origins, practices and future of safety pharmacology. J Pharmacol Toxicol Methods 2004;49:145-51
- Zbinden G. Neglect of function and obsession with structure in toxicity testing, Proc. 9th Int Cong Pharmacol. Volume 1 Macmillan; New York: 1984. p. 43-9
- Mellor HR, Bell AR, Valentin JP, Roberts RR. Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicol Sci 2011;120:14-32
- Cavero I. Exploratory safety pharmacology: a new safety paradigm to de-risk drug candidates prior to selection for regulatory science investigations. Expert Opin Drug Saf 2009;8:627-47
- Bass AS, Cartwright ME, Mahon C, et al. Exploratory drug safety: a discovery strategy to reduce attrition in development. J Pharmacol Toxicol Methods 2009;60:69-78
- ICH harmonised tripartite guideline preclinical safety evaluation of biotechnology-derived pharmaceuticals S6(R1). 1997 and 2011. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S6_R1/Step4/S6_R1_Guideline.pdf
- Rossini GP, Hartung T. Food for thought. towards tailored assays for cell-based approaches to toxicity testing. ALTEX 2012;29(4):359-72
- Glaxo Opens Clinical Trial Data. 2012. Available from: http://online.wsj.com/article/SB10000872396390444799904578050292700496194.html